NASDAQ:FTH Sensei Biotherapeutics (FTH) Stock Price, News & Analysis $28.02 +1.91 (+7.32%) Closing price 04:00 PM EasternExtended Trading$27.20 -0.82 (-2.94%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesSEC FilingsTrendsBuy This Stock About Sensei Biotherapeutics Stock (NASDAQ:FTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sensei Biotherapeutics alerts:Sign Up Key Stats Today's Range$24.59▼$28.3450-Day Range N/A52-Week Range$6.32▼$36.76Volume99,493 shsAverage Volume184,851 shsMarket Capitalization$37.55 millionP/E RatioN/ADividend YieldN/APrice Target$58.50Consensus RatingBuy Company Overview Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue. Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development. Sensei Biotherapeutics is headquartered in the United States and has focused primarily on advancing its programs through preclinical and clinical development rather than commercial sales. The company was founded to address challenges in cancer immunotherapy by engineering biologics that can be selectively activated in tumors. Sensei Biotherapeutics is led by an experienced management team and board with backgrounds in drug development and biotechnology, though leadership details can change over time.AI Generated. May Contain Errors. Read More Sensei Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreFTH MarketRank™: Sensei Biotherapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 11th out of 94 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingSensei Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialSensei Biotherapeutics has a consensus price target of $58.50, representing about 107.7% upside from its current price of $28.16.Amount of Analyst CoverageSensei Biotherapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Sensei Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($16.61) to ($3.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sensei Biotherapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sensei Biotherapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSensei Biotherapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for FTH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSensei Biotherapeutics does not currently pay a dividend.Dividend GrowthSensei Biotherapeutics does not have a long track record of dividend growth. News and Social Media4.0 / 5News Sentiment1.38 News SentimentSensei Biotherapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sensei Biotherapeutics this week, compared to 26 articles on an average week.Search Interest2 people have searched for FTH on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Sensei Biotherapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $1,188,822.00 in company stock, which represents 3.1502% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Sensei Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,188,822.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders7.00% of the stock of Sensei Biotherapeutics is held by insiders.Percentage Held by Institutions10.50% of the stock of Sensei Biotherapeutics is held by institutions.Read more about Sensei Biotherapeutics' insider trading history. Receive FTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FTH Stock News HeadlinesFaeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2026 | businesswire.comBrian Stephenson Acquires 831 Shares of Sensei Biotherapeutics (NASDAQ:FTH) StockJuly 2, 2026 | insidertrades.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.July 8 at 1:00 AM | Porter & Company (Ad)Sensei Biotherapeutics (NASDAQ:FTH) CFO Acquires $245,386.83 in StockJune 29, 2026 | americanbankingnews.comInsider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Buys $155,937.50 in StockJune 29, 2026 | americanbankingnews.comInsider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Purchases 6,250 SharesJune 27, 2026 | insidertrades.comInsider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CEO Purchases $55,446.56 in StockJune 25, 2026 | insidertrades.comSee More Headlines FTH Stock Analysis - Frequently Asked Questions How have FTH shares performed this year? Sensei Biotherapeutics' stock was trading at $16.65 on June 17, 2026. Since then, FTH shares have increased by 69.1% and is now trading at $28.1630. How were Sensei Biotherapeutics' earnings last quarter? Sensei Biotherapeutics, Inc. (NASDAQ:FTH) posted its earnings results on Friday, May, 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. How do I buy shares of Sensei Biotherapeutics? Shares of FTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today7/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 2 weeks, FTH's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FTH CIK1829802 WebN/A Phone(240) 243-8000FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Sensei Biotherapeutics$58.50 High Price Target$60.00 Low Price Target$57.00 Potential Upside/Downside+107.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($142.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-83.59% Return on Assets-256.50% Debt Debt-to-Equity RatioN/A Current Ratio14.39 Quick Ratio14.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.74 per share Price / Book1.91Miscellaneous Outstanding Shares1,340,000Free Float1,248,000Market Cap$37.74 million OptionableN/A Beta-0.26 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:FTH) was last updated on 7/8/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredThe window is closingWe printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline b...American Alternative | SponsoredJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
